NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company’s newly designated Series C Convertible Preferred Stock (the “Preferred Stock”). Pursuant to the Purchase Agreement, Blue Harbour purchased 60,000 shares of Preferred Stock for an aggregate p ...

BISHOP, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- North Bay Resources, Inc. (the “Company” or “North Bay”) (OTC: NBRI) is pleased to announce a private placement offering to residents of the United States (and globally as Canadian and non – United States Accredited Investors) who qualify as verified accredited investors pursuant to Rule 506(c) and Regulation D under the United States Securities Act of 1933. All US subscribers must complete and return the accreditation form and sufficient supporting informat ...

Core Viewpoint - Critical One Energy Inc. has successfully closed a non-brokered financing, raising CDN$1,000,000 through the issuance of 2,500,000 units at CDN$0.40 per unit, which will be utilized for exploration activities and general expenses [1][4]. Financing Details - The financing involved the issuance of units, each consisting of one common share and one-half common share purchase warrant, with full warrants allowing the purchase of one common share at CDN$0.60 for 18 months [2]. - A director participated in the financing, acquiring 230,000 units for a total of CDN$92,000, qualifying as a related party transaction [2][3]. Regulatory Compliance - The company relied on exemptions from valuation and minority approval requirements under Multilateral Instrument 61-101, as the transaction did not exceed 25% of the company's market capitalization [3]. Use of Proceeds - Proceeds from the private placement are earmarked for exploration activities at the Howells Lake Antimony Gold Project and for general administrative expenses [4]. Company Overview - Critical One Energy Inc. focuses on critical minerals and upstream energy, with a strategic position to meet the rising global demand for critical minerals, particularly through its antimony-gold exploration in Canada and uranium interests in Namibia [5].

Core Viewpoint - Artelo Biosciences, Inc. has entered into a definitive securities purchase agreement for an At-the-Market private placement, aiming to raise approximately $1.425 million to support clinical data announcements and general corporate purposes [1][2]. Group 1: Securities Offering Details - Artelo will issue 136,844 shares of common stock and 93,179 pre-funded warrants, along with warrants to purchase 460,046 shares at $5.82 per share and 230,023 shares at $10.00 per share [2]. - The offering aims to provide sufficient capital for announcing clinical data regarding two phase 1 studies for ART26.12 and a phase 2 study readout from the CAReS trial for ART27.13 [2]. - The company plans to allocate $250,000 of the net proceeds to purchase the digital currency SOL, with the remainder for general corporate and working capital purposes [2]. Group 2: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer, pain, and dermatological issues [4]. - The company is advancing a portfolio of product candidates aimed at addressing significant unmet medical needs across multiple diseases [4]. - Artelo is led by experienced biopharmaceutical executives and collaborates with respected researchers and technology experts to develop impactful therapies [4].

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces a non-brokered private placement to raise up to USD $925,000 through the issuance of up to 1,267,123 common share units ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- Mustang Energy Corp. (CSE: MEC, OTC: MECPF, FRA: 92T) (“Mustang” or the “Company”) is pleased to announce a non-brokered private placement (the “Offering”) for aggregate gross proceeds of up to C$3,000,000 from the sale of any combination of the following: non-flow through units of the Company (each, a “Unit”) at a price of C$0.14 per Unit;critical ...

The net proceeds of the Offering will be used for drilling at the Wild Dog Project, additional exploration activities in Papua New Guinea and for general and administrative expenses and working capital purposes, as further described in the Offering Document. Closing of the Offering is expected on or about July 3, 2025 or such other date as the Company and Lead Agent may agree and is subject to the approval of the TSX Venture Exchange. Eventus Capital Corp. has been appointed as a special advisor to the Comp ...

Core Points - Fitzroy Minerals Inc. plans to complete a non-brokered listed issuer financing exemption (LIFE) private placement, aiming to raise up to $12 million at a price of $0.30 per share, with a minimum offering amount of $8 million [1][2] - The company will also conduct a concurrent non-brokered private placement of up to $1 million through the issuance of up to 3,333,333 shares at the same price [3] - Proceeds from the private placements will be allocated for exploration activities, property commitments, general administrative costs, and working capital [4] Regulatory and Offering Details - The LIFE Offering is conducted under National Instrument 45-106 and will not have a hold period under Canadian securities laws [2] - Securities from the concurrent offering will be subject to a statutory hold period of four months and one day [3] - The closing of the private placements is expected around July 5, 2025, pending TSXV approval [5] Insider Participation - Insiders of the company are expected to participate in the concurrent offering, which may be considered a related party transaction but will be exempt from certain formal requirements [6] Company Overview - Fitzroy Minerals focuses on exploring and developing mineral assets in the Americas, with projects including Buen Retiro and Caballos in Chile, Taquetren in Argentina, and Cariboo in Canada [9]

Core Viewpoint - Cyclacel Pharmaceuticals has successfully completed a private placement of its convertible Series F Preferred Stock, raising gross proceeds of $3.0 million, which will be utilized for working capital and general corporate purposes [1][2]. Group 1: Financing Details - The private placement involved the issuance of convertible Series F Preferred Stock and warrants to purchase a total of 9,810,000 shares of common stock at varying exercise prices of $0.51, $0.60, and $0.68 per share [1]. - The offering closed on June 20, 2025, and the warrants will expire five years from the date of issuance [1]. - Each share of Preferred Stock is convertible into 3.27 shares of Common Stock, subject to stockholder approval as per Nasdaq listing rules [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes, which, along with existing cash, is expected to extend the company's cash runway into the third quarter of 2025 [2]. Group 3: Regulatory and Legal Aspects - The securities issued in the private placement have not been registered under the Securities Act of 1933 and were sold in reliance on Regulation S [4]. - The offering was conducted directly to investors without the involvement of a placement agent, underwriter, broker, or dealer [4]. Group 4: Company Overview - Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines, particularly through its anti-mitotic program, plogosertib, which targets PLK1 in various cancer types [7].

Goldstorm Metals Announces Upsizing of Previously Announced Private Placement Financing to Approximately $2.1 Million, with Participation by Eric SprottJune 19, 2025 3:55 PM EDT | Source: Goldstorm Metals Corp.Vancouver, British Columbia--(Newsfile Corp. - June 19, 2025) - Goldstorm Metals Corp. (TSXV: GSTM) (FSE: B2U) ("Goldstorm" or the "Company") is pleased to announce that, due to strong investor demand, it intends to increase the size of the Company's previously announced non-brokered pri ...